Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1034-1040

  Ishii, Hideki ^a,b   Kumada, Yoshitake ^b   Toriyama, Takanobu ^b   Aoyama, Toru ^b   Takahashi, Hiroshi ^b   Yamada, Shigeki ^b   Yasuda, Yoshinari ^a   Yuzawa, Yukio ^a   Maruyama, Shoichi ^a   Matsuo, Seiichi ^a   Matsubara, Tatsuaki ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA KYORITSU HOSPITAL   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ANGIOPLASTY, BALLOON; CONSTRICTION, PATHOLOGIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY; VASODILATOR AGENTS;

EID: 49149104807     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05761207     Document Type: Article

References (36)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974
2. Goldsmith DJA, Covic A: Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney Int 60: 2059-2078, 2001
3. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799-805, 1998
4. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606-1615, 1999
5. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: The Hemodialysis (HEMO) Study. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362, 2000
6. O'Hare AM, Johansen KL: Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 12: 2838-2847, 2001
7. Kudo T, Chandra FA, Ahn SS: The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: A 10 year experience. J Vasc Surg 41: 423-435, 2005
8. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M, Gabrielli L, Losa S, Stella A, Gargiulo M, Mantero M, Caminiti M, Ninkovic S, Curci V, Morabito A: Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: Prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 29: 620-627, 2005
9. Graziani L, Silvestro A, Bertone V, Manara E, Alicandri A, Parrinello G, Manganoni A: Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant 22: 1144-1149, 2007
10. Leskinen Y, Salenius JP, Lebtimäki T, Huhtala H, Saha H: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 40: 472-479, 2002
11. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of smooth muscle cell culture. J Cardiovasc Pharmacol 20: 900-906, 1992
12. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H: Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82: 144-147, 1998
13. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N: Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100: 21-26, 1999
14. Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ: Effect of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 86: 499-503, 2000
15. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS; Cilostazol for Restenosis Trial (CREST) Investigators: Coronary stent restenosis in patients treated with cilostazol. Circulation 112: 2826-2832, 2005
16. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, Onishi T, Ito N, Oshima F, Minamiguchi H, Kitakaze M, Nagata S: Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 69: 1256-1259, 2005
17. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31[Suppl]: 1-296, 2000
18. Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, Onuma Y, Yachi S, Nakajima H, Hara K. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv 69: 808-814, 2007
19. Aoyama T, Ishii H, Toriyama T, Takahashi H, Kasuga H, MD, Murakami R, Amano T, Uetani T, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T: Sirolimus-eluting stents versus bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 172: 56-60, 2008
20. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. A randomized comparison of a sirolimus-eluting stents versus standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
21. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003
22. Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE: Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109: 634-640, 2004
23. Nakazawa G, Tanabe K, Aoki J, Onuma Y, Yamamoto H, Higashikuni Y, Nakajima H, Hara K: Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice. Circ J 70: 1367-1371, 2006
24. Suzuki S, Kamihata H, Hata T, Hayashi F, Miura A, Yoshinaga M, Karakawa M, Kitaura Y: Success rate of implantation and mid-term outcomes of the sirolimus-eluting stent. Circ J 171: 15-19, 2007
25. Ikeda Y, Kikuchi M, Murakami H: Comparison of the inhibitory effects of cilostazol, acetylsalicylic and ticlopidine on platelet function ex vivo: Randomized, double blind cross-over study. Drug Research 37: 563-566, 1987
26. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H: Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 36: 313-320, 1988
27. Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S: Randomized comparison of cilostazol vs ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late loss. Am Heart J 144: 303-308, 2002
28. Viener A, Aviram M, Better OS, Brook JG: Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 43: 139-143, 1986
29. Notohamiprodjo M, Andrassy K, Bommer J, Ritz E: Dialysis membranes and coagulation system. Blood Purif 4: 130-141, 1986
30. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, Ogihara T: Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 35: 237-243, 2000
31. Aoki M, Morishita R, Matsushita H, Hayashi S, Nakagami H, Yamamoto K, Moriguchi A, Kaneda Y, Higaki J, Ogihara T: Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells: Potential role of p53 in regulation of vascular smooth muscle cell growth. Hypertension 34: 192-200, 1999
32. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T: Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 44: 1034-1042, 2001
33. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW: High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 25: 74-83, 1997
34. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K: Cilostzaol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44: 1408-1414, 2004
35. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS: Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. Stroke 36: 782-786, 2005
36. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381-386, 1992